2025 has been a year of recalibration. After a period of sustained caution, both corporates and investors are showing green shoots of renewed activity. Healthcare valuations have steadied and strategic dealmaking is re-emerging, particularly in mid-cap pharma, healthcare services, specialty pharma and biopharma/biotech. Private equity looks set to play a major part in dealmaking again next year, with GPs facing both pressure to sell assets and return capital to their LPs, whilst also deploying their dry powder. For assets where the most likely exit is an IPO, Jefferies believes there has been a significant dislocation in the valuations new investors are assuming for their eventual IPO exit because of the recent challenging IPO environment.
Read the full article: 2025 Jefferies Healthcare Temperature Check //
Source: https://www.jefferies.com/about/conferences-events/global-healthcare-conference-london/2025-temperature-check/